Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 6/20 | 0.51 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | PRKCH | P24723 | 2/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13839291 | 1.00 | CTRB1 (0.51) | CTRB1HMGB1PRKCBPRKCAPRKCH | |
| SCHEMBL13839315 | 0.93 | CTRB1 (0.60) | CTRB1HMGB1F2PSMB5PSMB8 | |
| SCHEMBL2786862 | 0.93 | CTRB1 (0.60) | CTRB1HMGB1F2PSMB5PSMB8 | |
| SCHEMBL2788043 | 0.91 | CTRB1 (0.49) | CTRB1HMGB1F2PSMB5PSMB8 | |
| SCHEMBL13839303 | 0.91 | CTRB1 (0.49) | CTRB1HMGB1F2PSMB5PSMB8 | |
| SCHEMBL15870016 | 0.91 | CTRB1 (0.49) | CTRB1HMGB1F2PSMB5PSMB8 | |
| SCHEMBL2787674 | 0.91 | CTRB1 (0.49) | CTRB1HMGB1F2PSMB5PSMB8 | |
| SCHEMBL12944967 | 0.90 | CTRB1 (0.51) | CTRB1HMGB1F2PSMB5PSMB8 | |
| SCHEMBL18827364 | 0.89 | CTRB1 (0.50) | CTRB1HMGB1PSMB5PSMB8 | |
| Hydrochloric Acid SCHEMBL2769059 | 0.89 | CTRB1 (0.50) | CTRB1HMGB1F2PSMB5PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD. (BM) | 2010-11-11 | — | — | US | disclosed |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | CTRB1 196/4885HMGB1 1428/4885PRKCB 785/4885 |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | CTRB1 196/4885HMGB1 1428/4885PRKCB 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.